Kurma Partners Launches EUR 250 Million Biofund IV
Company Announcements

Kurma Partners Launches EUR 250 Million Biofund IV

Eurazeo (FR:RF) has released an update.

Kurma Partners has announced the first close at EUR 140 million for its new Biofund IV, with a target of EUR 250 million and plans to make 16 to 20 new investments in innovative therapeutics. The fund, which has already completed three investments, continues Kurma’s strategy of collaborating with academic and industry professionals to foster Europe’s health innovation ecosystem. With cornerstone investments from Eurazeo, Bpifrance, and CSL, and following successful exits from the Biofund III portfolio, the new fund demonstrates investor confidence in Kurma’s approach to healthcare innovation.

For further insights into FR:RF stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks European Auto-Generated NewsdeskEurazeo Reports Strong Asset Management Growth in 2024
TipRanks European Auto-Generated NewsdeskEurazeo Announces Share Capital and Voting Rights
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App